Reappraisal of the hepatitis C virus-positive donor in solid organ transplantation

Current Opinion in Organ Transplantation

Volumn 20, Issue 3, 2015, Pages 267-275

  Patwardhan, Vilas R ^a   Curry, Michael P ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Hepatitis C virus positive donor; Liver transplant; Organ transplantation

Indexed keywords

CALCINEURIN INHIBITOR; DASABUVIR; INTERFERON; LEDIPASVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SOFOSBUVIR;

ALL CAUSE MORTALITY; ALLOGRAFT; CLINICAL OUTCOME; COMORBIDITY; DIALYSIS; EUROPE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEMODIALYSIS; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LIVER FIBROSIS; LIVER GRAFT; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; ORGAN DONOR; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SURVIVAL; UNITED STATES; ALLOTRANSPLANTATION; DONOR; HEPACIVIRUS; ISOLATION AND PURIFICATION;

HEPACIVIRUS; HEPATITIS C; HUMANS; ORGAN TRANSPLANTATION; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; WAITING LISTS;

EID: 85014687428     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000191     Document Type: Review

References (53)

1. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014; 59:2188–2195.
2. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the U.S. Gastroenterology 2015; 148:547–555.
3. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60:799–805.
4. Lunel F, Cadranel JF, Rosenheim M, et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology 2000; 119:1064–1074.
5. Miguel M, Sampaio MS, Kuo H-T, et al. Influence of preexisting hepatitis C virus antibody positivity in simultaneous pancreas-kidney transplant recipients. Transplantation 2010; 90:61–67.
6. Adam R, McMaster P, O’Grady JG, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003; 9:1231–1243.
7. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705–714.
8. Ellingson K, Seem D, Nowicki M, et al., For the Organ Procurement Organization Nucleic Acid Testing Yield Project Team. Estimated risk of human immunodeficiency virus and hepatitis C virus infection among potential organ donors from 17 organ procurement organizations in the United States. Am J Transplant 2011; 11:1201–1208.
9. Kucirka LM, Alexander C, Namuyinga R, et al. Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs. Am J Transplant 2009; 9:620–628.
10. Fabrizi F, Martin P, Dixit V, Messa P. Meta-analysis of observational studies: & hepatitis C and survival after renal transplant. J Viral Hepat 2014; 21:314–324. This is a meta-analysis of outcomes of renal transplantation in patients with HCV. This study found increased risk of mortality and graft loss in renal transplant recipients with HCV.
11. Kucirka LM, Singer AL, Ros RL, et al. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant 2010; 10:1238–1246.
12. Younossi Z, Stepanova M, Saab S, et al. The association of hepatitis C virus & infection and postliver transplant diabetes: data from 17000 HCV-infected transplant recipients. Aliment Pharmacol Therap 2015; 41:209–217. This observation study reviewed scientific registry for transplant recipients data comparing HCV patients to hepatitis B virus controls and found an increased risk of post-transplant diabetes in patients transplanted for hepatitis C.
13. Neumann UP, Berg T, Bahra M, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol 2004; 41:830–836.
14. Firpi RJ, Clark V, Soldevila-Pico C, et al. The natural history of hepatitis C cirrhosis after liver transplantation. Liver Transpl 2009; 15:1063–1071.
15. Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl 2001; 7:762–768.
16. Álvaro E, Abradelo M, Fuertes A, et al. Liver transplantation from antihepatitis C virus-positive donors: our experience. Transplant Proc 2012; 44:1475–1478.
17. Velidedeoglu E, Desai NM, Campos L, et al. The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation 2002; 73:582–587.
18. Burr AT, Li Y, Tseng JF, et al. Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg 2011; 35:1590–1595.
19. Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int 2010; 23:1038–1044.
20. Lai JC, O’Leary JG, Trotter JF, et al. Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. Liver Transpl 2012; 18:532–538.
21. Khapra AP, Agarwal K, Fiel MI, et al. Impact of donor age on survival and fibrosis progression in patients with hepatitis C undergoing liver transplantation using HCVþ allografts. Liver Transpl 2006; 12:1496–1503.
22. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18:716–726.
23. Carbone M, Mutimer D, Neuberger J. Hepatitis C virus and nonliver solid organ transplantation. Transplantation 2013; 95:779–786.
24. Scott DR, Wong JKW, Spicer TS, et al. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 2010; 90:1165–1171.
25. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78:745–750.
26. Bloom RD, Sayer G, Fa K, et al. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant 2005; 5:139–144.
27. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007; 18:1584–1593.
28. Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007; 14:697–703.
29. Bucci JR, Lentine KL, Agodoa LY, et al. Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS/UNOS database. Clin Transpl 2004; 18:51–61.
30. Scalea JR, Barth RN, Munivenkatappa R, et al. Shorter waitlist times and && improved graft survivals are observed in patients who accept hepatitis C virusþ renal allografts. Transplantation 2014. [Epub ahead of print] This study establishes that patients who accept HCV-positive allografts spend less time on the renal transplant waiting list, which contributed to improved death-censored graft survival.
31. Marelli D, Bresson J, Laks H, et al. Hepatitis C-positive donors in heart transplantation. Am J Transplant 2002; 2:443–447.
32. Ong JP, Barnes DS, Younossi ZM, et al. Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 1999; 30:1293–1298.
33. Gudmundsson GS, Malinowska K, Robinson JA, et al. Five-year follow-up of hepatitis C-naïve heart transplant recipients who received hepatitis C-positive donor hearts. Transplant Proc 2003; 35:1536–1538.
34. Gasink LB, Blumberg EA, Localio AR, et al. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. J Am Med Assoc 2006; 296:1843–1850.
35. Haji SA, Starling RC, Avery RK, et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant 2004; 23:277–283.
36. Zaroff JG, Rosengard BR, Armstrong WF, et al. Consensus conference report: maximizing use of organs recovered from the cadaver donor: cardiac recommendations. Circulation 2002; 106:836–841.
37. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update – a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:745–755.
38. Fong T-L, Cho YW, Hou L, et al. Outcomes after lung transplantation and practices of lung transplant programs in the United States regarding hepatitis C seropositive recipients. Transplantation 2011; 91:1293–1296.
39. Ortiz J, Gunselman J, Javed I, et al. Are hepatitis C-positive allografts in simultaneous pancreas-kidney transplantation underutilized? Ann Transplant 2012; 17:39–44.
40. Wolfe RA, McCullough KP, Schaubel DE, et al. Calculating life years from transplant (LYFT): methods for kidney and kidney-pancreas candidates. Am J Transplant 2008; 8:997–1011.
41. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42:448–456.
42. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 (suppl 2):S36–S44.
43. Blasco A, Forns X, Carrión JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43:492–499.
44. Carrión JA, Navasa M, Bosch J, et al. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006; 12:1791–1798.
45. Crespo G, Mariño Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142:1373–1383.
46. Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with & decompensated cirrhosis, pre and posttransplantation. J Hepatol 2014; 61:S120–S131. This is a comprehensive review of hepatitis C treatment in patients pre-liver and post-liver transplantation.
47. Selzner N, Guindi M, Renner EL, Berenguer M. Immune-mediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55:207–217.
48. Fiel MI, Schiano TD. Plasma cell hepatitis (de-novo autoimmune hepatitis) developing post liver transplantation. Curr Opin Organ Transplant 2012; 17:287–292.
49. Levitsky J, Fiel MI, Norvell JP, et al. Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. Gastroenterology 2012; 142:1132–1139.
50. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of && compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148:108–117. This clinical trial evaluated the safety and efficacy of hepatitis C treatment after liver transplantation with 24 weeks of sofosbuvir and ribavirin.
51. Kwo PY, Mantry PS, Coakley E, et al. An interferon-free antiviral regimen for && HCV after liver transplantation. N Engl J Med 2014; 371:2375–2382. This clinical trial evaluated the safety and efficacy of hepatitis C treatment in patients with minimal fibrosis after liver transplant with ombitasvir, ABT-450, ritonavir, dasabuvir, and ribavirin for 24 weeks.
52. Reddy KR, Everson GT, Flamm SL, et al. Ledipasvir/sofosbuvir with ribavirin for the treatment of HCV in patients with post transplant recurrence: preliminary results of a prospective, multicenter study. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA; 2014. Abstract #8.
53. Brown RS, Reddy KR, O’Leary JG, et al. Safety and efficacy of new DAA-based therapy for hepatitis C post-transplant: interval results from the HCV-TARGET longitudinal, observational study. Presented at the 65th Annual Meeting of the American Association for the Study of Liver Diseases; Boston, MA; 2014. Abstract LB-4.